Track Iovance Biotherapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Iovance Biotherapeutics, Inc. IOVA · Stock Open Iovance Biotherapeutics, Inc. in new tab

7.76 USD
EPS
-0.49
P/B
4.42
ROE
-29.12
Beta
0.84
Target Price
14.50 USD
Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc.

🧾 Earnings Recap – Q2 2026

Shares jumped 46.1% following a standout quarter driven by record Amtagvi revenue and an all-time high 56% margin, both materially exceeding guidance and market expectations.

  • Q2 total revenue reached approximately $99 million, up 66% year-over-year and 39% sequentially.
  • Amtagvi sales surged to about $91 million, exceeding the $79–81 million guidance range by a wide margin and growing 51% sequentially.
  • Gross margin expanded sharply to 56%, up from 41% in Q1, reflecting improved operational efficiency and scale.
  • Proleukin revenues were $9 million, down from $11 million in Q1 due to wholesaler inventory timing, but full-year contribution remains steady.
  • Commercial momentum is supported by more than 50 patients treated monthly, broad pipeline progress, and a promising regulatory outlook including Fast Track designations.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 23, 2027
EPS-0.49
Book Value1.76
Price to Book4.42
Debt/Equity5.56
% Insiders0.822%
Growth
Revenue Growth0.80%
Estimates
Forward P/E-68.14
Forward EPS-0.11
Target Mean Price14.50

DCF valuation

Model fair value for Iovance Biotherapeutics, Inc. (IOVA)
Result
Sign in to run the valuation for IOVA.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
10 analysts · consensus Buy · mean target 14.50 USD (low 8.00, high 20.00) · as of 16 Nov 2026
Low 8.00
Mean 14.50
High 20.00
Price 7.76
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Iovance Biotherapeutics, Inc. Logo Iovance Biotherapeutics, Inc. Analysis (IOVA)

United States Health Care Official Website Stock

Is Iovance Biotherapeutics, Inc. a good investment? Iovance Biotherapeutics, Inc. (IOVA) is currently trading at 7.76 USD. Market analysts have a consensus price target of 14.50 USD. This suggests a potential upside from current levels.

Earnings Schedule: Iovance Biotherapeutics, Inc. is expected to release its next earnings report on Feb. 23, 2027. The market consensus estimate for Forward EPS is -0.11.

Investor FAQ

Does Iovance Biotherapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Iovance Biotherapeutics, Inc.?

Iovance Biotherapeutics, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 23, 2027. The company currently has a trailing EPS of -0.49.

Company Profile

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in Philadelphia, Pennsylvania.

Exchange Ticker
NGM (Sweden) IOVA
FRA (Germany) 2LB.F
LSE (United Kingdom) 0JDK.L
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
May 26, 2010 24:1
Sept. 26, 2013 1:100
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion